# A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Source: https://onco.cc/trials/nct06505395/  
OnCo record `nct06505395` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SYHX2008 injection in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.

## Summary

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) is a phase 2 interventional study registered as NCT06505395 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 90 participants planned, started 2024-07-30 and due to reach its primary completion in 2027-08-01. Interventions recorded: SYHX2008 injection and Sandostatin LAR@.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06505395
- Phase: 2
- Setting: A Phase Ⅱ Randomized, Parallel-group, Open-label, Active-controlled Trial to Assess the Efficacy, Safety and Pharmacokinetics of the Long-acting Octreotide Subcutaneous Injection (SYHX2008) Versus Octreotide Microspheres (Sandostatin LAR@) in Patients With GEP-NET
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06505395: https://clinicaltrials.gov/study/NCT06505395

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06505395.json